Literature DB >> 7359612

Erythromycin ototoxicity.

P Thompson, R P Wood, L Bergstrom.   

Abstract

Erythromycin is considered one of the safest antibiotics in common use today. In its otolaryngologic use, the authors have found it effective in treating acute suppurative sinusitis and occasionally otitis media, when combined with sulfonamides. There are few complications of erythromycin administration. Probably the least generally acknowledged of these is ototoxicity. There have been three reports of six cases with ototoxic complications from erythromycin, primarily from administration of its intravenous form. The authors present a case study of an 18 year old girl in severe renal failure, who suffered a reversible sensorineural hearing loss from high doses of an oral erythromycin preparation. The clinical manifestations of this case are compared to those previously reported.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7359612

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  5 in total

Review 1.  Vancomycin- and erythromycin-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  Mycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome.

Authors:  E Wolinsky; C R Horsburgh; D L Cohn; R B Roberts; H Masur; R Miller; A Y Tsang; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

3.  Erythromycin (2 X 1 g) as a Regimen for community-acquired pneumonia.

Authors:  H P Simmen; R Lüthy
Journal:  Infection       Date:  1982       Impact factor: 3.553

4.  Sensorineural hearing loss in patients reaching chronic renal failure in childhood.

Authors:  M L Mancini; L Dello Strologo; P M Bianchi; L Tieri; G Rizzoni
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

Review 5.  Ototoxicity of Non-aminoglycoside Antibiotics.

Authors:  Leonard P Rybak; Vickram Ramkumar; Debashree Mukherjea
Journal:  Front Neurol       Date:  2021-03-09       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.